
AKTS Stock Forecast & Price Target
AKTS Analyst Ratings
Bulls say
Aktis Oncology is forecasted to have a bright future as a result of their promising pipeline products, AKY-1189 and AKY-2519. With a strong collaboration agreement generating revenue and a discounted cash flow-based valuation methodology projecting a market value of $1.93B and a 12-month price target of $35 per share, there is strong potential for growth and development. Risks to the price target include negative clinical results, delays in advancing pipeline candidates, and competitive risks; however, with sufficient cash to fund operations until 2029, the company has the resources to overcome these challenges and achieve success.
Bears say
Aktis Oncology is a clinical-stage oncology company focused on developing targeted radiopharmaceuticals for solid tumors. Despite a partnership generating revenue, Aktis is a highly speculative investment due to its lack of current products on the market and ongoing losses. A major factor in the negative outlook is the uncertainty surrounding the success of Aktis' pipeline programs, as well as the potential for future dilution of shares to fund their development.
This aggregate rating is based on analysts' research of Aktis Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
AKTS Analyst Forecast & Price Prediction
Start investing in AKTS
Order type
Buy in
Order amount
Est. shares
0 shares